BAY 1143269

Drug Profile

BAY 1143269

Alternative Names: BAY-1143269

Latest Information Update: 15 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Bayer terminates a phase I trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA and United Kingdom (PO) (NCT02439346)
  • 01 May 2016 Bayer suspends recruitment in a phase I trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA and United Kingdom (PO) (NCT02439346)
  • 15 Jun 2015 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, United Kingdom (PO) (NCT02439346)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top